A phase 1b study of SEA-BCMA in patients with relapsed or refractory multiple myeloma
Verified

What's the purpose of this trial?

This trial is testing a monoclonal antibody called SEA-BCMA. Researchers want to know what dose is safest, what side effects patients may have, and if SEA-BCMA will work to treat multiple myeloma.

SEA-BCMA is a type of treatment called a monoclonal antibody. Antibodies are part of your immune system. Usually, they help protect you from getting sick. With SEA-BCMA, we are using an antibody designed to stick to the multiple myeloma cells in your body. The antibody sends a signal to other cells in your immune system that kill the cancer cells. It also stops the multiple myeloma cells from getting a signal that makes them grow. The antibody may also stick to some non-cancer cells in your body.

They are asking you to be in this study because you have multiple myeloma that has come back or did not get better with your last therapy.

This trial is currently open and accepting patients.


What's being studied?

  • SEA-BCMA is a monoclonal antibody that targets the B-Cell Maturation Antigen (BCMA) and is made with Sugar Engineered Antibody (SEA) technology. Researchers believe this approach may improve immune response to cancer cells.

What will happen during the trial?

This is a Phase 1b dose exploration and expansion study. The study is evaluating the safety, tolerability and efficacy of SEA-BCMA by itself, and when combined with Dexamethasone.

The dose expansion part of this study is being conducted in two parts, Part B (SEA-BCMA monotherapy) and Part C (SEA-BCMA and Dexamethasone). This trial is open label, which means that both you and the researchers running the study will know what therapies you will receive.

Part B (SEA-BCMA Monotherapy)

This part of the study is evaluating the safety and tolerability of SEA-BCMA when given by itself. There are two phases in this part of the study, induction and maintenance therapy. This part of the study may enroll up to 40 patients.

  • Induction Phase – This part of the study will last for two cycles, with each cycle lasting 28 days. Participants will receive SEA-BCMA every week during induction. At the end of the eight weeks, participants may move into the maintenance phase of the study if their myeloma has not progressed.
  • Maintenance Phase – This part of the study is also set up in 28 day cycles. Participants will receive SEA-BCMA every two weeks.

Part C (SEA-BCMA and Dexamethasone) 

This part of the study is evaluating the safety and tolerability of SEA-BCMA when combined with Dexamethasone. This part of the study is organized into two groups (cohorts) with different dosing schedules.

  • Cohort 1 - This group is organized in 28 day cycles. Patients will receive SEA-BCMA (by intravenous infusion) every two weeks, and Dexamethasone (either a pill or intravenous infusion) weekly.
  • Cohort 2 - This group is organized in 28 day cycles. Patients will receive SEA-BCMA (by intravenous infusion) every week for the first two cycles, and Dexamethasone (either a pill or intravenous infusion) weekly. If the participants myeloma has not worsened, they may then receive SEA-BCMA every two weeks, and Dexamethasone (either a pill or intravenous infusion) weekly.

After you have stopped receiving SEA-BCMA, study investigators will ask you to participate in a follow up visit or phone call every 3 months until the study ends.

You can decide to stop being in the study at any time. You can still go to your regular hospital or clinic for treatment after you leave this study.

If you decide to stop treatment with SEA-BCMA, you will still be asked to come back to the hospital or clinic for follow-up tests. You may also be asked to take part in follow-up phone calls and visits.

During the study, Seattle Genetics will pay for:

  • the study drug, SEA-BCMA
  • any procedures done only for the study

You or your insurance company will be billed for your regular medical care. It's possible your insurance may not cover all of your regular medical care costs. You are responsible for the part your insurance doesn’t pay. If you’re not sure how this applies to you, ask your doctor or the study staff.

You won’t be paid for taking part in this study or for any discoveries made in this study.

You may be able to have some of your costs for taking part in the study paid back, like travel and lodging. Please call SparkCures at (888) 828-2206 or ask someone from the study staff for more information.


Additional Trial Information

Phase 1

Enrollment: 185 patients (estimated)

View More

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required. Create your account or call us today for help (888) 828-2206.

  • Are at least 18 years old
  • Have relapsed or refractory myeloma.
  • Have received at least 3 prior lines of therapy for your myeloma, including an immunomodulatory agent, proteasome inhibitor, and an anti-CD38 antibody and not have other therapies that could provide clinical benefit available
  • Have not previously had a targeted BCMA therapy.
  • Have not had an allogeneic stem cell transplant.
  • No prior CAR T-cell therapy unless completed at least 8 weeks prior to first dose of SEA-BCMA
View Additional Criteria

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.

California

Stanford Cancer Institute

Stanford, CA

Open and Accepting

Colorado

Rocky Mountain Cancer Center Aurora

Aurora, CO

Open and Accepting

Florida

Sylvester Comprehensive Cancer Center University of Miami Health System

Miami, FL

Open and Accepting

Iowa

Holden Comprehensive Cancer Center University of Iowa Hospitals and Clinics

Iowa City, IA

Open and Accepting

Kansas

University of Kansas Cancer Center

Kansas City, KS

Open and Accepting

Missouri

Alvin J. Siteman Cancer Center Washington University Medical Campus

St. Louis, MO

Open and Accepting

New York

Weill Cornell Medicine

New York, NY

Open and Accepting

University of Rochester Medical Center James P. Wilmot Cancer Center

Rochester, NY

Open and Accepting

Oregon

Willamette Valley Cancer Institute (Eugene)

Eugene, OR

Open and Accepting

Texas

Texas Oncology Austin Midtown

Austin, TX

Open and Accepting

Washington

Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

SparkCures Verified

SparkCures is working closely with Seattle Genetics to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.

Learn more about how we work with trial sponsors